Drug recall · December 11, 2019
EXPAREL, Bupivicaine Liposome Injectable Suspension recall
Why: Sub Potent Drug: Out of Specification (OOS)
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira Pharmaceuticals, Inc. San Diego, CA 92121. NDC: 65250-266-20,
- Lots / codes
Pacira Lot #: 19-5002, Patheon manufacturer Lot #: 098214; Exp. Date: Dec 2019
- Quantity
- 910 20 mL vials
- Company
- Pacira Pharmaceuticals, Inc., San Diego, CA
- Distribution
- Distributed Nationwide in the USA
- Initiated
- November 21, 2019 · Voluntary: Firm initiated
- Classified
- December 10, 2019
- Reported
- December 11, 2019
- Ended
- June 3, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupivacaine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.